Home＞BUSINESS
EA Pharma Licenses Secondary Hyperparathyroidism Med AJT240 to JW Pharma(Nov.2.2017)
EA Pharma, a gastroenterology subsidiary of Eisai, said on October 31 that it has cut a licensing deal with South Korea’s JW Pharmaceutical, granting rights to develop and market its AJT240 for the treatment of secondary hyperparathyroidism in hemodialysis patients in South Korea ...
(LOG IN FOR FULL STORY)
-
-
Fuji Pharma Poised to Develop New Biosimilar in Women’s Health/Acute Care
Jul.19
- Belviq Didn’t Increase CV Events in Outcome Study: Eisai Jul.19
- Entyvio Filed for Crohn’s Disease in Japan: Takeda Jul.19
- Teva Takeda to Wind Up Sale of 48 Products towards Stable Supply Jul.18
- Xofluza Hits Primary Endpoint in High Risk Flu Patients: Shionogi Jul.18
- Fuji Pharma Poised to Develop New Biosimilar in Women’s Health/Acute Care(Jul.19)
- Lawmakers Question Rationale for PMD Law Amendment as LDP Launches Debate(Jul.19)
- Belviq Didn’t Increase CV Events in Outcome Study: Eisai(Jul.19)
- Entyvio Filed for Crohn’s Disease in Japan: Takeda(Jul.19)
- Scope of Japan-EU GMP Mutual Recognition Agreement for Pharmaceuticals Expanded: MHLW(Jul.19)
